Jonathan Biller sells Vertex shares (NASDAQ: VRTX) across Dec 2025–Feb 2026

Rhea-AI Filing Summary

Vertex Pharmaceuticals reported insider sales by Jonathan P. Biller of Common stock under Rule 144. The filing lists individual transactions including 347 shares on 12/03/2025 for $155,803.00, 1,925 shares on 02/11/2026 for $886,327.75, 988 shares on 02/13/2026 for $493,012.00, 2,476 shares on 02/17/2026 for $1,211,902.96, and 1,244 shares on 02/18/2026 for $589,257.92.

The report shows these dispositions were made from holdings registered with Fidelity Brokerage Services LLC and includes a separate entry for 945 shares vested on 02/24/2026 as restricted stock vesting.

Insights

Corporate Governance Analyst

Insider reported multiple Rule 144 dispositions totaling several thousand shares across December 2025–February 2026.

The filing itemizes five sales by Jonathan P. Biller with per-transaction share counts and dollar proceeds: 347, 1,925, 988, 2,476, and 1,244 shares on specified dates, and a separate 945-share restricted stock vesting on 02/24/2026. These are standard Rule 144 dispositions and include broker information (Fidelity Brokerage Services LLC).

Reported insider sales alone do not indicate firm-wide changes; their significance depends on total beneficial ownership and trading intent. Subsequent public filings or Form 4 amendments may provide additional ownership context.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/25/2026 - 09:41 AM Learn about SEC filing dates

FAQ

What transactions did VRTX insider Jonathan P. Biller report?

The filing reports five sales: 347 shares ($155,803.00), 1,925 shares ($886,327.75), 988 shares ($493,012.00), 2,476 shares ($1,211,902.96), and 1,244 shares ($589,257.92). Dates are provided for each trade.

Were any shares from restricted stock vesting reported in the VRTX filing?

Yes. The filing lists 945 shares as Restricted Stock Vesting on 02/24/2026, indicating an issuer-side vesting event separate from the listed dispositions.

Which broker handled the reported VRTX transactions?

The transactions are associated with Fidelity Brokerage Services LLC, with an address listed as 900 Salem Street, Smithfield RI 02917 and an NASDAQ reference in the filing.

Do these Form 144 entries state total beneficial ownership after the sales?

The excerpt lists individual sales and vesting but does not state a consolidated post-transaction beneficial ownership total, so aggregate ownership after these dispositions is not provided in the excerpt.

What time span do the reported VRTX sales cover?

The listed transactions span from 12/03/2025 through 02/18/2026, with an additional vesting entry on 02/24/2026 shown in the filing.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917	945	459600.75	254034190	02/25/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	02/24/2026	Restricted Stock Vesting	Issuer			945	02/24/2026	Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Jonathan P. Biller 50 Northern Avenue Boston MA 02210	Common	12/03/2025	347	155803.00
Jonathan P. Biller 50 Northern Avenue Boston MA 02210	Common	02/11/2026	1925	886327.75
Jonathan P. Biller 50 Northern Avenue Boston MA 02210	Common	02/13/2026	988	493012.00
Jonathan P. Biller 50 Northern Avenue Boston MA 02210	Common	02/17/2026	2476	1211902.96
Jonathan P. Biller 50 Northern Avenue Boston MA 02210	Common	02/18/2026	1244	589257.92

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)